Dr. Miner joined Oklahoma Foundation for Digestive Research in 1996 as President and Medical Director and serves on the OFDR Board of Directors. He is also Clinical Professor of Medicine at the University of Oklahoma. Before joining OFDR, he was Professor of Medicine and Director of the Division of Gastroenterology at the University of Kansas School of Medicine for 19 years. While on the faculty, he received special recognition awards for his service at the University of Kansas. He is a Fellow of the American College of Physicians, a Fellow of the American College of Gastroenterology, and an American Gastroenterology Association Fellow. He has served as the Regional Head of the Professional Education Committee of the Crohn's and Colitis Foundation. His contributions to scientific literature include more than 200 articles, book chapters and abstracts. He lectures widely on topics related to gastroenterology and is recognized nationally and internationally for his expertise in Inflammatory Bowel Disease, GERD, motility disorders, pelvic floor disorders and mast cells.

Dr. Miner received his medical degree from the University of Colorado, School of Medicine. He completed his medical internship at Kings County Hospital, State University of New York, Downstate Medical Center, his medical residency at the Society of the New York Hospital, Cornell University and his Fellowship in Gastroenterology at the University of Colorado.

Dr. Miner has served as an individual consultant to industry and as a consultant through participation in Medical Advisory Boards. Dr. Miner currently serves on Advisory Boards for ARYx Therapeutics, AstraZeneca Pharmaceuticals, Atlantic Healthcare, Axcan Pharma Inc., Biogen Idec, ISIS Pharmaceuticals, Proctor and Gamble Pharmaceuticals, Salix Pharmaceuticals Inc., UCB Pharmaceuticals, and Ventrus Biosciences Inc. He also serves as a consultant for Abbott, Allergan, ARYx Therapeutics, AstraZeneca, Atlantic Healthcare, Axcan, Biogen, Centocor Research and Development, Inc., Moveitis, Ocera, Pozen Inc., Salix, Sanofi-aventis, Schering Plough Healthcare, Takeda Pharma North America, Vecta Ltd., Ventrus Biosciences Inc., Wyeth and UCB. Areas of national and international expertise include: Inflammatory Bowel Disease, Functional Gastrointestinal disorders including Functional Heartburn, Dyspepsia, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Visceral Hypersensitivity, Mast cell and eosinophil gastrointestinal disorders, Anorectal Physiology and the management of constipation and fecal incontinence.

Oklahoma Foundation for Digestive Research

OFDR is a private, non-profit medical research foundation. Our mission is to advance basic science and clinical research in gastrointestinal disease, treat patients with such diseases, participate in the training of physicians, and to educate the public about gastrointestinal illnesses. Our free-standing clinical research center is affiliated with the private gastroenterology practice of Dr. Philip B. Miner, Jr., M.D., board-certified gastroenterologist. Dr. Miner joined OFDR in 1996 as President and Medical Director. He is also Clinical Professor of Medicine at the University of Oklahoma. Before joining OFDR, he was Professor of Medicine and Director of the Division of Gastroenterology at the University of Kansas for 19 years. His contributions to the scientific literature include more than 200 articles, book chapters and abstracts. He lectures widely on topics related to gastroenterology and is recognized nationally and internationally for his expertise in Inflammatory Bowel Disease, motility disorders, anorectal manometry and mast cells. He has served on advisory boards to several major pharmaceutical companies.

OFDR encompasses both clinical research and a basic sciences laboratory. Our staff of 22 includes 4 full-time clinical research coordinators, 2 GI laboratory technicians, and 1 Physician's Assistant in addition to our basic sciences personnel and administrative staff.

OFDR offers many unique and valuable aspects to sponsors and patients alike. Because we focus ONLY on research in gastroenterology, the level of knowledge, experience and expertise our staff and physicians are able to provide in these diseases is unmatched.

Clinical Research Experience

To date, OFDR has conducted over 275 clinical trials in gastroenterology including Phase I-IV, Rx-OTC switch, and post-marketing studies. Within the sub-specialty of gastroenterology, our interests include:

• Inflammatory Bowel Disease
o Crohn's disease
o Ulcerative Colitis

• Motility disorders
o Irritable Bowel Syndrome
o Constipation
o Non-Ulcer Dyspepsia
o Gastroparesis

• Gastroesophageal Reflux Disease
o Erosive and Non-Erosive Esophagitis
o Provocative meals for heartburn sufferers
o Gastroesophageal Mucosal Damage
o NSAID damage
http://www.centerwatch.com/news-resources/research-centers/profile-details.aspx?ProfileID=496

 Active Control, Double-blind, Double-dummy, Parallel-group, Randomized Study to Assess the Effect of VECAM 40/300, Administered at Bedtime, vs. Esomeprazole 20 mg, Administered 30-60 Min. Before Dinner, on Daytime and Nighttime GERD Symptoms

The study is designed to assess the effect and safety of oral administration of VECAM 40/300 administered at bedtime compared to Esomeprazole 20 mg administered 30-60 minutes before dinner, for control of nighttime and daytime HB and other 24 hour GERD symptoms.

The rational for the study is based on the contention that VECAM exhibits potent inhibition of acid secretion and because of its mechanism of action, it can be administered at bedtime without food. Such timing of drug dosing will allow effective inhibition of nighttime acid secretion. Because of its mechanism of action, VECAM exhibits improved 24-hour inhibition of acid secretion and hence, its bedtime administration will not compromise its effect during the daytime. This improved control of acid secretion will predictably result in better control of nighttime as well as daytime heartburn (HB) symptoms.

Estimated Enrollment:80
Study Start Date:December 2009
Estimated Study Completion Date: June 2010
Estimated Primary Completion Date:June 2010 (Final data collection date for primary outcome measure

Ages Eligible for Study: 18 Years to 75 Years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No

 A Phase I Double-blind, Randomized, Comparator-controlled Study of the Safety and Tolerability of N-acetylcysteine Plus Mesalamine Enema in Subjects With Left-sided Ulcerative Colitis

This Phase I study will be a closely monitored trial of a small number of subjects to establish, preliminarily, the tolerability and safety of two ALTH12 enema formulations: ALTH12-1:4 and ALTH12-2:4. The study will be conducted in two parts. The first part will be the assessment of the safety and tolerability of a single dose of ALTH12-1:4 or the comparator, mesalamine (4.0g 5-ASA) followed by an assessment of repeated administrations of study drug (ALTH12-1:4 or comparator) for 6 weeks. The second part will be the same assessment for ALTH12-2:4. Three subjects will be enrolled in each cohort: 2 to receive ALTH12 enema therapy and 1 subject to receive comparator enema therapy. A total of up to 9 patients will be enrolled in this study, allowing for up to 3 replacement or additional patients.

Estimated Enrollment:9
Study Start Date:November 2009
Estimated Study Completion Date:April 2010
Estimated Primary Completion Date:March 2010 (Final data collection date for primary outcome measure)

Ages Eligible for Study: 18 Years to 64 Years
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No